ASND vs. TEVA: Ascendis Pharma vs. Teva Pharmaceutical Stock Comparison

Company Profile

Ascendis Pharma (ASND) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ASND is classified in Biotechnology while TEVA is classified in Pharmaceuticals.

Ascendis Pharma (ASND) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but Ascendis Pharma (ASND) at 118.78% is the standout with ROE above its industry range; Teva Pharmaceutical (TEVA) at 6.65% also sits in the top quartile.

Ascendis Pharma (ASND) at 70.85% converts revenue to bottom-line profit above its industry’s benchmark range, while Teva Pharmaceutical (TEVA) at 2.94% keeps roughly the typical share for its industry.

Both Ascendis Pharma (ASND) at 64.98% and Teva Pharmaceutical (TEVA) at 27.40% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Ascendis Pharma (ASND) at 98.03% sits in the top revenue growth quartile, while Teva Pharmaceutical (TEVA) at 4.31% is closer to the peer norm — faster top-line expansion for ASND.

Neither Ascendis Pharma (ASND) nor Teva Pharmaceutical (TEVA) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Ascendis Pharma (ASND) at 2.99 keeps current ratio within its industry’s typical mid-range, while Teva Pharmaceutical (TEVA) at 0.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TEVA.

Ascendis Pharma (ASND) at 0.31 is near its industry mid-range for debt-to-equity ratio, while Teva Pharmaceutical (TEVA) at 2.13 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither Ascendis Pharma (ASND) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Ascendis Pharma (ASND) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Ascendis Pharma (ASND) at 19.68 is near its industry’s usual P/E ratio, while Teva Pharmaceutical (TEVA) at 99.09 sits above its peer range — an unusually expensive price for TEVA’s trailing earnings.

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while Ascendis Pharma (ASND) at 16.14 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.

Teva Pharmaceutical (TEVA) at 6.23 is valued about in line with its industry on P/B ratio, while Ascendis Pharma (ASND) at 10.45 carries an above-peer premium to book — ASND is pricier on assets.

Valuation Metrics